Mingbo Wang, Huicheng Lv, Long Han, Haisheng Jia, Lifeng Zhang, Lei Wang, Aimin He, Yu Du
{"title":"Combination of Isoliquiritigenin and Vancomycin Alleviates Staphylococcus aureus-Induced Bone Infection in Rats","authors":"Mingbo Wang, Huicheng Lv, Long Han, Haisheng Jia, Lifeng Zhang, Lei Wang, Aimin He, Yu Du","doi":"10.1111/apm.70056","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p><i>Staphylococcus aureus</i> (<i>S. aureus</i>)-induced osteomyelitis presents therapeutic challenges due to antibiotic resistance. Isoliquiritigenin (ISL), a licorice-derived chalcone, exhibits antibacterial and anti-inflammatory properties. This study evaluated vancomycin (VAN) combined with ISL against methicillin-resistant <i>S. aureus</i> (MRSA)-induced implant-related osteomyelitis. A rat model was established by tibial MRSA inoculation with simultaneous Kirschner wire implantation. Four weeks postinfection, rats were divided into five groups: normal, model, VAN (50 mg/kg), ISL (100 mg/kg), and VAN + ISL. After 14 days of treatment, combined therapy significantly reduced bone infection severity and histopathological scores versus monotherapies (<i>p</i> < 0.001), decreased serum inflammatory markers (IL-6, TNF-α, IL-1β, and CRP; <i>p</i> < 0.001), and reduced bacterial loads in bone/wire (<i>p</i> < 0.001). In vitro, ISL (50 μM) attenuated MRSA-induced inflammatory response in MC3T3-E1 osteoblasts by suppressing NF-κB and MAPK signaling, while promoting osteogenesis via increased Runx2/BMP2/ALP expression, activated BMP/Smad signaling, and enhanced mineralization. Overall, VAN + ISL combination therapy outperforms monotherapy by concurrently eradicating MRSA, suppressing inflammation, and promoting bone repair, representing a promising synergistic strategy for recalcitrant osteomyelitis.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"133 9","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70056","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Staphylococcus aureus (S. aureus)-induced osteomyelitis presents therapeutic challenges due to antibiotic resistance. Isoliquiritigenin (ISL), a licorice-derived chalcone, exhibits antibacterial and anti-inflammatory properties. This study evaluated vancomycin (VAN) combined with ISL against methicillin-resistant S. aureus (MRSA)-induced implant-related osteomyelitis. A rat model was established by tibial MRSA inoculation with simultaneous Kirschner wire implantation. Four weeks postinfection, rats were divided into five groups: normal, model, VAN (50 mg/kg), ISL (100 mg/kg), and VAN + ISL. After 14 days of treatment, combined therapy significantly reduced bone infection severity and histopathological scores versus monotherapies (p < 0.001), decreased serum inflammatory markers (IL-6, TNF-α, IL-1β, and CRP; p < 0.001), and reduced bacterial loads in bone/wire (p < 0.001). In vitro, ISL (50 μM) attenuated MRSA-induced inflammatory response in MC3T3-E1 osteoblasts by suppressing NF-κB and MAPK signaling, while promoting osteogenesis via increased Runx2/BMP2/ALP expression, activated BMP/Smad signaling, and enhanced mineralization. Overall, VAN + ISL combination therapy outperforms monotherapy by concurrently eradicating MRSA, suppressing inflammation, and promoting bone repair, representing a promising synergistic strategy for recalcitrant osteomyelitis.
期刊介绍:
APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.